|
|
||||||||||
|
J Am Coll Cardiol, 1996; 27:1207-1213 © 1996 by the American College of Cardiology Foundation |
Alfred Hospital and Baker Medical Research Institute, Prahran, Victoria, Australia.
OBJECTIVES. We sought to examine the efficacy of dietary supplementation of L-arginine on endothelium-dependent vasodilation in patients with congestive heart failure. BACKGROUND. Endothelial dysfunction, as evidenced by a diminished response to such vasodilators as acetylcholine, is well defined in patients with heart failure. These responses are improved by intraarterial infusion with L-arginine. Because L-arginine is a semi-essential amino acid, we investigated the effects of dietary L-arginine on endothelium-dependent vasodilation in these patients. METHODS. Twenty patients with heart failure (New York Heart Association functional class III/IV, mean [+/- SE] age 51.3 +/- 1.7 years) and seven healthy control subjects (mean age 52.6 +/- 3.3 years) were studied. All patients continued taking their usual treatment. Responses to acetylcholine and sodium nitroprusside were determined using forearm plethysmography. Patients with heart failure received either L-arginine (20 g/day every day for 28 days) or placebo (vehicle syrup in equal amounts) in a double-blind protocol. The calculated power of the study was between 62% and 80% to detect a 30% to 40% change in area under the dose-response (forearm vascular resistance) curve. RESULTS. Responses to acetylcholine, but not to sodium nitroprusside, were significantly attenuated in patients with heart failure compared with control subjects (mean area under curve [AUC], control subjects vs. patients with heart failure: 1,125.4 +/- 164.5 vs. 617.3 +/- 116.6 U, p < 0.05, by Student t test). A significant increase in urea and aspartate transaminase levels in patients receiving active L-arginine treatment was observed. Responses to acetylcholine (AUC; before vs. after L-arginine: 641.5 +/- 126.7 vs. 695.9 +/- 151.9 U) and sodium nitroprusside were not affected by either L-arginine or placebo. CONCLUSIONS. Endothelial dysfunction was apparent in patients with heart failure despite rigorous vasoactive treatment. Oral administration with L-arginine was ineffective in influencing endothelial function in these patients.
This article has been cited by other articles:
![]() |
S. G. West, A. Likos-Krick, P. Brown, and F. Mariotti Oral L-Arginine Improves Hemodynamic Responses to Stress and Reduces Plasma Homocysteine in Hypercholesterolemic Men J. Nutr., February 1, 2005; 135(2): 212 - 217. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. L. Gornik and M. A. Creager Arginine and Endothelial and Vascular Health J. Nutr., October 1, 2004; 134(10): 2880S - 2887S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Parnell, J. P. F. Chin-Dusting, J. Starr, and D. M. Kaye In vivo and in vitro evidence for ACh-stimulated L-arginine uptake Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H395 - H400. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tousoulis, C. Antoniades, C. Tentolouris, G. Goumas, C. Stefanadis, and P. Toutouzas L-Arginine in cardiovascular disease: dream or reality? Vascular Medicine, August 1, 2002; 7(3): 203 - 211. [Abstract] [PDF] |
||||
![]() |
H. A. Walker, E. McGing, I. Fisher, R. H. Boger, S. M. Bode-Boger, G. Jackson, J. M. Ritter, and P. J. Chowienczyk Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: Lack of effect of oral l-arginine on endothelial function, oxidative stress and exercise performance J. Am. Coll. Cardiol., August 1, 2001; 38(2): 499 - 505. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.C. Mendes Ribeiro, T.M.C. Brunini, J.C. Ellory, and G.E. Mann Abnormalities in L-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure Cardiovasc Res, March 1, 2001; 49(4): 697 - 712. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Kaye, B. A. Ahlers, D. J. Autelitano, and J. P. F. Chin-Dusting In Vivo and In Vitro Evidence for Impaired Arginine Transport in Human Heart Failure Circulation, November 28, 2000; 102(22): 2707 - 2712. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hambrecht, L. Hilbrich, S. Erbs, S. Gielen, E. Fiehn, N. Schoene, and G. Schuler Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation J. Am. Coll. Cardiol., March 1, 2000; 35(3): 706 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C Ray, M. E Landis, and V. M Miller Effects of dietary l-arginine on the reactivity of canine coronary arteries Vascular Medicine, November 1, 1999; 4(4): 211 - 217. [Abstract] [PDF] |
||||
![]() |
S. D. Katz, T. Khan, G. A. Zeballos, L. Mathew, P. Potharlanka, M. Knecht, and J. Whelan Decreased Activity of the L-Arginine–Nitric Oxide Metabolic Pathway in Patients With Congestive Heart Failure Circulation, April 27, 1999; 99(16): 2113 - 2117. [Abstract] [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |